How to buy Sage Therapeutics stock | $69.6

Sage Therapeutics, Inc is a biotechnology business based in the US. Sage Therapeutics shares (SAGE) are listed on the NASDAQ and all prices are listed in US Dollars. Sage Therapeutics employs 298 staff and has a trailing 12-month revenue of around 0.00.

Sage Therapeutics stock price (NASDAQ: SAGE)

Use our graph to track the performance of SAGE stocks over time.

Sage Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-28.

Latest market close	$69.60
52-week range	$42.85 - $98.39
50-day moving average	$56.04
200-day moving average	$72.40
Wall St. target price	$91.26
PE ratio	3.83
Dividend yield	N/A (0%)
Earnings per share (TTM)	$11.66

Buy Sage Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Sage Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Sage Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sage Therapeutics price performance over time

Historical closes compared with the close of $69.6 from 2021-05-28

1 week (2021-07-23)	N/A
1 month (2021-07-02)	24.17%
3 months (2021-05-03)	-11.85%
6 months (2021-01-30)	N/A

1 year (2020-07-30)	N/A
2 years (2019-07-30)	N/A
3 years (2018-07-30)	N/A
5 years (2016-07-30)	N/A

Is Sage Therapeutics under- or over-valued?

Valuing Sage Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sage Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Sage Therapeutics's P/E ratio

Sage Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, Sage Therapeutics shares trade at around 4x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Sage Therapeutics's PEG ratio

Sage Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.74. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sage Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Sage Therapeutics's EBITDA

Sage Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $663.6 million.

The EBITDA is a measure of a Sage Therapeutics's overall financial performance and is widely used to measure a its profitability.

Sage Therapeutics financials

Revenue TTM	$1.1 billion
Operating margin TTM	59.19%
Gross profit TTM	$820.9 million
Return on assets TTM	27.23%
Return on equity TTM	44.67%
Profit margin	57.21%
Book value	$34.30
Market capitalisation	$2.6 billion

TTM: trailing 12 months

Shorting Sage Therapeutics shares

There are currently 3.7 million Sage Therapeutics shares held short by investors – that's known as Sage Therapeutics's "short interest". This figure is 3.1% down from 3.9 million last month.

There are a few different ways that this level of interest in shorting Sage Therapeutics shares can be evaluated.

Sage Therapeutics's "short interest ratio" (SIR)

Sage Therapeutics's "short interest ratio" (SIR) is the quantity of Sage Therapeutics shares currently shorted divided by the average quantity of Sage Therapeutics shares traded daily (recently around 1.4 million). Sage Therapeutics's SIR currently stands at 2.63. In other words for every 100,000 Sage Therapeutics shares traded daily on the market, roughly 2630 shares are currently held short.

However Sage Therapeutics's short interest can also be evaluated against the total number of Sage Therapeutics shares, or, against the total number of tradable Sage Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sage Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Sage Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0729% of the tradable shares (for every 100,000 tradable Sage Therapeutics shares, roughly 73 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sage Therapeutics.

Find out more about how you can short Sage Therapeutics stock.

Sage Therapeutics share dividends

We're not expecting Sage Therapeutics to pay a dividend over the next 12 months.

Sage Therapeutics share price volatility

Over the last 12 months, Sage Therapeutics's shares have ranged in value from as little as $42.85 up to $98.385. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sage Therapeutics's is 1.9869. This would suggest that Sage Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Sage Therapeutics overview

Sage Therapeutics, Inc. , a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co.

Frequently asked questions

What percentage of Sage Therapeutics is owned by insiders or institutions?
Currently 12.425% of Sage Therapeutics shares are held by insiders and 92.609% by institutions. How many people work for Sage Therapeutics?
Latest data suggests 298 work at Sage Therapeutics. When does the fiscal year end for Sage Therapeutics?
Sage Therapeutics's fiscal year ends in December. Where is Sage Therapeutics based?
Sage Therapeutics's address is: 215 First Street, Cambridge, MA, United States, 02142 What is Sage Therapeutics's ISIN number?
Sage Therapeutics's international securities identification number is: US78667J1088 What is Sage Therapeutics's CUSIP number?
Sage Therapeutics's Committee on Uniform Securities Identification Procedures number is: 78667J108